US FDA approves revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2

News
Article

The encapsulated cell therapy from Neurotech Pharmaceuticals is the first FDA-approved treatment for MacTel

A phone with the US Food and Drug Administration (FDA) logo on the screen. Image credit: ©gguy – stock.adobe.com

MacTel is a bilateral, neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss. Image credit: ©gguy – stock.adobe.com

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (Encelto) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel).

At the date of approval, Encelto is the first and only FDA-approved Treatment for MacTel. Encelto utilises an encapsulated cell therapy (ECT) technology designed to continually deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina to assist in slowing the progression of the disease.

Neurotech’s ECT platform is a cell-based gene therapy delivery system designed to provide long-term, sustained delivery of therapeutic proteins for the treatment of chronic eye diseases. The platform consists of a small, semi-permeable capsule that is surgically implanted, containing proprietary allogeneic retinal pigment epithelium (RPE) cells genetically engineered to produce specific therapeutic proteins for targeted disease treatment.

The company stated in a press release that the approval from the FDA was based on results from two phase 3 trials. Results from the trials showed that after placement of the implant, Encelto significantly slowed the loss of macular photoreceptors in MacTel patients over 24 months.

Richard Small, CEO of Neurotech Pharmaceuticals, and Charles C Wykoff, MD, PhD, Retinal Consultants of Texas and clinical investigator, commented on the approval in a press release from the company.

“Today marks an extraordinary milestone for patients, the retina community, and Neurotech,” said Small. “I would like to express my gratitude to clinical study participants, clinical investigators and their teams, and the entire Neurotech organization who have helped make this a reality.”

“I have seen the impact that MacTel can have on patients and their quality of life,” said Wykoff. “Now with an FDA approved treatment, I am confident that Encelto will be able to meaningfully slow disease progression for many patients affected by MacTel, allowing them the opportunity to preserve more functional vision over time.”

MacTel is a bilateral, neurodegenerative disease of the retina in adults with characteristic localised retinal degeneration that causes progressive and irreversible vision loss and secondary alterations of the retinal vasculature.

The company stated that Encelto is expected to be available in the United States for patients starting in June 2025.

Reference

  1. Neurotech’s ENCELTO (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel). Press release. Neurotech Pharmaceuticals. Published March 6, 2025. Accessed March 6, 2025. https://www.neurotechpharmaceuticals.com/neurotechs-enceltotm-revakinagene-taroretcel-lwey-approved-by-the-fda-for-the-treatment-of-macular-telangiectasia-type-2-mactel/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.